Long-term regression after discontinuation of regorafenib administered for sorafenib-refractory hepatocellular carcinoma

A patient with hepatocellular carcinoma(HCC) staged Barcelona Clinic for Liver Cancer stage B started chemotherapy because of intrahepatic recurrence after hepatic segmentectomy. Regorafenib was started as a second-line treatment due to refractory to sorafenib treatment, but was discontinued after 26 months due to side effects. After two years of follow-up, the patients achieved unexpected long-term regression. We present the potential of regorafenib effect for anti-tumor immunity through possible pharmacological mechanisms.

Automated summary

A patient with hepatocellular carcinoma(HCC) received chemotherapy for intrahepatic recurrence after hepatic segmentectomy. Regorafenib was used as a second-line treatment, but discontinued due to side effects. Unexpected long-term regression was observed after two years of follow-up, suggesting the potential of regorafenib for anti-tumor immunity through pharmacological mechanisms.